BioSpace News Archive

Genetown

Replimune to Present at Two Upcoming Investor Conferences - Nov 01, 2021

Replimune Group, Inc., a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, announced that members from the Replimune management team will present and host investor meetings.

November 1, 2021
·
1 min read
Business

Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals, Ltd. today reported third quarter 2021 financial results and recent portfolio execution.

November 1, 2021
·
16 min read
Genetown

Candel Therapeutics Announces Upcoming Data Presentations on its Oncolytic Viral Immunotherapies

Candel Therapeutics, Inc. today announced its participation in upcoming medical and scientific conferences.

November 1, 2021
·
6 min read
Business

BioVie Announces the Appointment of a New Chief Medical OfficerDr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease

BioVie Inc. announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company’s new Chief Medical Officer.

November 1, 2021
·
6 min read
BioForest

Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the submission of a pre-Investigational New Drug (IND) briefing package to the U.S. Food and Drug Administration (FDA) for its broad-spectrum protease inhibitor CDI-45205

November 1, 2021
·
4 min read
Business

Kinnate Biopharma Inc. in Collaboration with Guardant Health Announces Initial Findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study

Kinnate Biopharma Inc. today announced a collaboration with Guardant Health, a leading precision oncology company, focused on characterizing the prevalence of patients with advanced solid tumors bearing BRAF Class I, II and III alterations.

November 1, 2021
·
6 min read
FDA

FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

Novartis announced today that the US Food and Drug Administration (FDA) approved Scemblix® (asciminib) for the treatment of chronic myeloid leukemia (CML) in two distinct indications.

November 1, 2021
·
17 min read
Business

I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer Appointments

I-Mab (the “Company”) (Nasdaq: IMAB), today announced the appointment of John Long as the Company’s Chief Financial Officer and Jielun Zhu as the Company’s Chief Strategy Officer, both effectively immediately.

November 1, 2021
·
5 min read
Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

Lipocine Inc. (NASDAQ: LPCN), announced today that three abstracts have been selected for poster presentations during the upcoming The Liver Meeting® 2021, organized by the American Association for the Study of Liver Diseases (AASLD) to take place November 12-15, 2021.

November 1, 2021
·
3 min read
Biotech Beach

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29–November 1, 2021.

November 1, 2021
·
8 min read